AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.
about
Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptionsCan immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in ChinaDNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent VirusCharacteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trialA human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.Immunologic strategies for HIV-1 remission and eradication.Immune interventions in HIV infection.Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL.HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers.Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruziIsotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection.The need for treatment interruption studies and biomarker identification in the search for an HIV cure.The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 InfectionRelevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.A curative regimen would decrease HIV prevalence but not HIV incidence unless targeted to an ART-naïve populationThe size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruptionTherapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.Human immunodeficiency virus-1 vaccine design: where do we go now?Therapeutic vaccines against HIV infection.Dendritic cell dysregulation during HIV-1 infection.Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.Adenovirus-vectored Ebola vaccines.Toward a cure for HIV--Seeking effective therapeutic vaccine strategies.Novel immunological strategies for HIV-1 eradicationEvaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruptionLFA-1 Mediates Cytotoxicity and Tissue Migration of Specific CD8+ T Cells after Heterologous Prime-Boost Vaccination against Trypanosoma cruzi Infection.Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption.A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.Immune Interventions to Eliminate the HIV Reservoir.EFFECT OF SHORT-TERM ART INTERRUPTION ON LEVELS OF INTEGRATED HIV DNA.
P2860
Q26777442-C1E26BEF-7433-44A2-AA8D-62D02E4B2FA0Q26865388-3AC376F1-196C-4EBF-9E27-7A48C59269C2Q28544731-4AF9A421-431A-470E-B515-F5A43151C844Q28554534-64F10F57-7E6C-41E8-A939-BAFEE4431836Q28730828-8BED4402-D71E-4DDB-AF76-62F8212CFD86Q30934059-0B1D3BE0-B474-47D5-BF05-6007F8793279Q33896523-597E8B0D-77C7-46A5-AD29-B5D3DA64D83AQ34351326-375564B3-BB9D-42A1-A169-61E8F504AE8DQ34550802-8D01254B-42CA-47DD-B3D6-EC6CE14FAC3BQ34699130-4ADC1F36-323D-494C-9E92-DA56D6D18E3FQ34713877-49CAB21C-5CEA-4CDE-A8E2-E4ADF556CC26Q34743309-B8524921-FEE4-4B51-AD0D-FEF50616BD9AQ34931648-28FEF301-613F-4C54-9115-8D9FC8692C9EQ35826668-7F4DB52F-943D-4069-884C-44CB049FFB75Q35928987-66AB4125-A3DD-4B3A-AD0D-D5579FE215C0Q36462210-EC746EE7-09F2-4253-9B8F-6A93CF107BE8Q36474557-EB15ACA0-1527-41EE-80E6-DD7A29C97310Q36481572-F47C0BFF-65E4-4AB6-A79C-71AA5F6AF825Q36611180-CB1C7ACB-89C2-477F-938E-2093106D3EFEQ36824388-4BC39007-B699-4AE9-BB1F-BCD1C77527A0Q36846254-C27B16DE-37B7-4B82-B8F2-9435C8E33AC4Q37014116-5C66CAB2-7151-4F4F-A44A-85797768E6B5Q37381097-2E1DECAD-7767-49EE-8C2B-9DECCA6A2FE8Q37499526-ABBBC7FE-7882-4529-AF40-13D3575BA9EFQ37801269-02710104-522E-47CD-AACB-6EA559BEA9F7Q38013505-EF79360B-B6B2-4AD4-8FFC-3F91C3B7A852Q38114911-B1997737-1579-4313-BA63-C3644A8CB9CCQ38415577-86536742-5A72-413C-92DD-D82D32B5A4A5Q38569831-2D7BCAC1-D801-4E0D-902C-A315C71265FCQ38626469-FF923CBC-6524-40CB-BBD3-2D78E7B9B226Q38915896-1C836562-E053-413B-9D9A-220594DED068Q41980459-2B8310E2-EC1F-446C-9904-73250199D072Q42682937-A569B69B-A780-4EFC-95DA-50DCA1CA8191Q47553711-573A314C-6D86-4690-AED2-04732F84031FQ47568717-CC9735C0-EDEF-439C-976D-08E3F0727F42Q47600062-A9A5216D-9828-40DE-8469-13E389689A64Q52624999-5ABA8340-C414-41BB-8F8F-5F31E25CC274
P2860
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
AIDS clinical trials group 519 ...... essing the HIV-1 core protein.
@ast
AIDS clinical trials group 519 ...... essing the HIV-1 core protein.
@en
AIDS clinical trials group 519 ...... essing the HIV-1 core protein.
@nl
type
label
AIDS clinical trials group 519 ...... essing the HIV-1 core protein.
@ast
AIDS clinical trials group 519 ...... essing the HIV-1 core protein.
@en
AIDS clinical trials group 519 ...... essing the HIV-1 core protein.
@nl
prefLabel
AIDS clinical trials group 519 ...... essing the HIV-1 core protein.
@ast
AIDS clinical trials group 519 ...... essing the HIV-1 core protein.
@en
AIDS clinical trials group 519 ...... essing the HIV-1 core protein.
@nl
P2093
P2860
P921
P356
P1476
AIDS clinical trials group 519 ...... essing the HIV-1 core protein.
@en
P2093
AIDS Clinical Trials Group 5197 Study Team
Barbara Schock
Cathy Battaglia
Daniel R Kuritzkes
Danilo Casimiro
Devan Mehrotra
Hongying Wang
John Spritzler
Michael M Lederman
P2860
P304
P356
10.1086/655468
P407
P50
P577
2010-09-01T00:00:00Z